NEVANAC 3 mg/ml eye drops, suspension
nepafenac
NEVANAC contains the active substance nepafenac which belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
NEVANAC is used in adults:
To prevent and relieve eye pain and inflammation after cataract surgery in the eye.
To reduce the risk of macular edema (inflammation in the back of the eye) after cataract surgery in the eye in diabetic patients.
Consult your doctor, pharmacist or nurse before you start using NEVANAC:
Avoid exposure to sunlight during treatment with NEVANAC.
Do not use contact lenses after cataract surgery. Your doctor will tell you when you can start using contact lenses again. NEVANAC contains benzalkonium chloride
Do not use this medicine in children and adolescents under 18 years old as the safety and efficacy have not been established in this population.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
NEVANAC may affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.
Tell your doctor if you are using medicines that reduce blood clotting (warfarin) or other NSAIDs. These medicines may increase the risk of bleeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Women who may become pregnant should use effective contraception during treatment with NEVANAC. The use of NEVANAC is not recommended during pregnancy. Do not use NEVANAC unless clearly indicated by your doctor.
If you are breast-feeding, NEVANAC may pass into breast milk. However, no effects on the breast-fed child are expected. You can use NEVANAC during breast-feeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Do not drive or use machines until your vision is clear. Immediately after applying NEVANAC you may notice that your vision becomes blurred for a moment.
This medicine contains 0.15 mg of benzalkonium chloride in each 3 ml equivalent to 0.05 mg/ml.
NEVANAC contains a preservative, benzalkonium chloride, which may be absorbed by soft contact lenses and may alter the color of contact lenses. Remove contact lenses before using this medicine and wait 15 minutes before putting them back. Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal diseases (the transparent layer on the front of the eye). Consult your doctor if you feel any unusual sensation, itching or pain in the eye after using this medicine.
Follow exactly the instructions of administration of this medicine given to you by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use NEVANAC only in your eyes. Do not swallow or inject.
One drop in the affected eye(s), once a day. Use it at the same time every day.
Start 1 day before cataract surgery. Continue on the day of surgery. Then use it for the period of time that your doctor tells you, which may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent the formation of macular edema and improve vision) after your surgery.
Wash your hands before starting.
If you are applying drops in both eyes, repeat the above steps for the other eye. It is not necessary to close and shake the bottle between administrations of both eyes. Screw the cap back on the bottle immediately after use.
If a drop falls outside the eye, try again.
If you are using other eye drops, wait at least 5 minutes between applying NEVANAC and the other drops.
Contact your doctor for detailed instructions. Do not apply more drops until it is time for your next dose.
Apply a single dose as soon as you remember. If it is almost time for your next dose, do not apply the missed dose and continue with your regular dosing schedule. Do not use a double dose to make up for missed doses. Do not apply more than one drop in the affected eye(s).
Do not stop using NEVANAC without consulting your doctor. You can usually continue using the eye drops unless the effects are severe.
If you have any other questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may have a higher risk of experiencing corneal side effects (problems on the surface of the eye), if you:
Contact your doctor immediately if your eyes become red or if the pain increases while you are using the drops. This may be due to inflammation of the eye surface with or without loss or damage of cells or inflammation of the colored part of the eye (iritis). These side effects have been seen in up to 1 in 100 people.
The following side effects have been seen with NEVANAC 3 mg/ml eye drops, suspension or NEVANAC 1 mg/ml eye drops, suspension or with both:
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date is the last day of the month stated.
Do not store above 25°C. Keep the bottle in the outer carton to protect it from light.
To avoid infections, discard the bottle 4 weeks after first opening. Write the date of opening on the space provided on the carton.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
NEVANAC eye drops, suspension (eye drops) is a liquid (a pale yellow to dark orange suspension) presented in a plastic bottle with a screw cap. The bottle may be in a bag.
Each pack contains a 3 ml bottle.
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
S.A. Alcon-Couvreur N.V.
Rijksweg 14
B-2870 Puurs
Belgium
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
You can get more information on this medicine by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | |
Ceska republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 | |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: + 421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Sverige Novartis Sverige AB Tel: +46 8 732 32 00 | |
United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698370 |
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu